Skip to main content
Top
Published in: Rheumatology International 2/2021

01-02-2021 | Giant Cell Arteritis | Case Based Review

Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature

Authors: Delamo I. Bekele, Kenneth J. Warrington, Matthew J. Koster

Published in: Rheumatology International | Issue 2/2021

Login to get access

Abstract

To describe the clinical characteristics, management, and outcome of a series of patients with giant cell arteritis (GCA) and inflammatory bowel disease (IBD). Patients with both GCA and IBD evaluated between 1/1/1996 and 12/30/2018 were retrospectively identified. Clinical characteristics, laboratory parameters, radiologic features, histopathology, management and outcomes were abstracted. A systematic literature review identifying patients with IBD and GCA was performed via a Medline and EMBASE search from inception through December 31 2019. Six patients were identified with GCA and IBD (66% male). Five (83%) had ulcerative colitis (UC) and one had Crohn’s disease (CD). Diagnosis of IBD preceded GCA in four patients with an average interval of 30 years (range 14–42). Average time to IBD diagnosis in those with prior GCA diagnosis was 1.5 years. During mean follow-up of 4.3 years, GCA relapse was infrequent with only one patient with relapse observed. Systematic literature review identified six additional patients with confirmed coexistence of GCA and IBD. Similar to the current series, male sex was more common and ulcerative colitis was the predominant IBD phenotype. The current study reports findings from the largest single-institution case-series of co-existent GCA and IBD. In contrast to Takayasu arteritis with co-existent IBD, which displays a predilection for female sex and Crohn’s disease phenotype, both the current study and review of literature demonstrate a stronger association of GCA with male sex and ulcerative colitis. Further studies addressing a potential pathophysiologic connection between GCA and IBD are suggested.
Literature
1.
go back to reference Wilson JC et al (2015) Inflammatory bowel disease and the risk of autoimmune diseases. J Crohn’s Colitis 10(2):186–193CrossRef Wilson JC et al (2015) Inflammatory bowel disease and the risk of autoimmune diseases. J Crohn’s Colitis 10(2):186–193CrossRef
2.
go back to reference Cohen R et al (2008) Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis 14(6):738–743CrossRef Cohen R et al (2008) Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001–2002. Inflamm Bowel Dis 14(6):738–743CrossRef
3.
go back to reference Halling ML et al (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 23(33):6137–6146CrossRef Halling ML et al (2017) Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 23(33):6137–6146CrossRef
4.
go back to reference Sy A et al (2016) Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 45(4):475–482CrossRef Sy A et al (2016) Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum 45(4):475–482CrossRef
5.
go back to reference Yavne Y et al (2018) Giant cell arteritis and inflammatory bowel disease - Is there a connection? Results from a population-based study. Autoimmun Rev 17(11):1134–1137CrossRef Yavne Y et al (2018) Giant cell arteritis and inflammatory bowel disease - Is there a connection? Results from a population-based study. Autoimmun Rev 17(11):1134–1137CrossRef
6.
go back to reference Bernstein CN et al (2016) World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol 50(10):803–818CrossRef Bernstein CN et al (2016) World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015. J Clin Gastroenterol 50(10):803–818CrossRef
7.
go back to reference Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122–1128CrossRef
8.
go back to reference Ronchetto F, Pistono PG (1993) Temporal arteritis in a patient with ulcerative colitis. Coincidental association or (immuno) pathogenetic link? Recent Prog Med 84(1):54–56 Ronchetto F, Pistono PG (1993) Temporal arteritis in a patient with ulcerative colitis. Coincidental association or (immuno) pathogenetic link? Recent Prog Med 84(1):54–56
9.
go back to reference Gobron C et al (2010) Unilateral carotid granulomatous arteritis and Crohn's disease. 166(5):542–546. Gobron C et al (2010) Unilateral carotid granulomatous arteritis and Crohn's disease. 166(5):542–546.
10.
go back to reference Jacob A et al (1990) Ulcerative colitis and giant cell arteritis associated with sensorineural deafness. J Laryngol Otol 104(11):889–890CrossRef Jacob A et al (1990) Ulcerative colitis and giant cell arteritis associated with sensorineural deafness. J Laryngol Otol 104(11):889–890CrossRef
11.
go back to reference Sanges S et al (2016) Giant cell arteritis and ulcerative colitis: an unusual association. Semin Arthritis Rheum 46(1):e3-5CrossRef Sanges S et al (2016) Giant cell arteritis and ulcerative colitis: an unusual association. Semin Arthritis Rheum 46(1):e3-5CrossRef
12.
go back to reference Watanabe R et al (2016) Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol 2(2):126–137CrossRef Watanabe R et al (2016) Giant cell arteritis: from pathogenesis to therapeutic management. Curr Treatm Opt Rheumatol 2(2):126–137CrossRef
13.
go back to reference Chandran AK et al (2015) The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol 44(3):215–218CrossRef Chandran AK et al (2015) The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol 44(3):215–218CrossRef
14.
go back to reference Labarca C et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356CrossRef Labarca C et al (2016) Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 55(2):347–356CrossRef
15.
go back to reference Martinez-Lado L et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90(3):186–193CrossRef Martinez-Lado L et al (2011) Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 90(3):186–193CrossRef
16.
go back to reference Koster MJ et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46(5):501–508CrossRef Koster MJ et al (2019) Efficacy of methotrexate in real-world management of giant cell arteritis: a case-control study. J Rheumatol 46(5):501–508CrossRef
17.
go back to reference Mahr AD et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef Mahr AD et al (2007) Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 56(8):2789–2797CrossRef
18.
go back to reference Koster MJ et al (2018) Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology 57(suppl_2):ii32-ii42 Koster MJ et al (2018) Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology 57(suppl_2):ii32-ii42
19.
go back to reference Koster MJ, Warrington KJ (2017) Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 46(7–8 Pt 2):e205–e213CrossRef Koster MJ, Warrington KJ (2017) Classification of large vessel vasculitis: can we separate giant cell arteritis from Takayasu arteritis? Presse Med 46(7–8 Pt 2):e205–e213CrossRef
20.
go back to reference Tuckwell K et al (2017) Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum 46(5):657–664CrossRef Tuckwell K et al (2017) Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin Arthritis Rheum 46(5):657–664CrossRef
Metadata
Title
Giant cell arteritis associated with inflammatory bowel disease: a case-series and review of the literature
Authors
Delamo I. Bekele
Kenneth J. Warrington
Matthew J. Koster
Publication date
01-02-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04727-w

Other articles of this Issue 2/2021

Rheumatology International 2/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.